JP2020164547A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020164547A5 JP2020164547A5 JP2020109574A JP2020109574A JP2020164547A5 JP 2020164547 A5 JP2020164547 A5 JP 2020164547A5 JP 2020109574 A JP2020109574 A JP 2020109574A JP 2020109574 A JP2020109574 A JP 2020109574A JP 2020164547 A5 JP2020164547 A5 JP 2020164547A5
- Authority
- JP
- Japan
- Prior art keywords
- dose
- cdp
- topoisomerase inhibitor
- administered
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 33
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 31
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 31
- 239000003814 drug Substances 0.000 claims 15
- 229940079593 drug Drugs 0.000 claims 8
- 229940124597 therapeutic agent Drugs 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 4
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical group C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 3
- 229940127093 camptothecin Drugs 0.000 claims 3
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 3
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 2
- 230000000340 anti-metabolite Effects 0.000 claims 2
- 229940100197 antimetabolite Drugs 0.000 claims 2
- 239000002256 antimetabolite Substances 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229960004117 capecitabine Drugs 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- 230000009610 hypersensitivity Effects 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 239000002207 metabolite Substances 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 150000003230 pyrimidines Chemical class 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 230000001988 toxicity Effects 0.000 claims 2
- 231100000419 toxicity Toxicity 0.000 claims 2
- 230000002485 urinary effect Effects 0.000 claims 2
- 230000036325 urinary excretion Effects 0.000 claims 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 229960005529 CRLX101 Drugs 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 229920000858 Cyclodextrin Polymers 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022135758A JP2022166327A (ja) | 2009-09-15 | 2022-08-29 | 癌の治療法 |
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24275209P | 2009-09-15 | 2009-09-15 | |
| US61/242,752 | 2009-09-15 | ||
| US31703910P | 2010-03-24 | 2010-03-24 | |
| US61/317,039 | 2010-03-24 | ||
| US33215010P | 2010-05-06 | 2010-05-06 | |
| US61/332,150 | 2010-05-06 | ||
| US38185110P | 2010-09-10 | 2010-09-10 | |
| US61/381,851 | 2010-09-10 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017196769A Division JP2017226708A (ja) | 2009-09-15 | 2017-10-10 | 癌の治療法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022135758A Division JP2022166327A (ja) | 2009-09-15 | 2022-08-29 | 癌の治療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020164547A JP2020164547A (ja) | 2020-10-08 |
| JP2020164547A5 true JP2020164547A5 (cg-RX-API-DMAC7.html) | 2021-01-07 |
Family
ID=43758997
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012529881A Expired - Fee Related JP5855568B2 (ja) | 2009-09-15 | 2010-09-15 | 癌の治療法 |
| JP2014223985A Withdrawn JP2015025020A (ja) | 2009-09-15 | 2014-11-04 | 癌の治療法 |
| JP2016045695A Pending JP2016106143A (ja) | 2009-09-15 | 2016-03-09 | 癌の治療法 |
| JP2017196769A Withdrawn JP2017226708A (ja) | 2009-09-15 | 2017-10-10 | 癌の治療法 |
| JP2020109574A Pending JP2020164547A (ja) | 2009-09-15 | 2020-06-25 | 癌の治療法 |
| JP2022135758A Withdrawn JP2022166327A (ja) | 2009-09-15 | 2022-08-29 | 癌の治療法 |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012529881A Expired - Fee Related JP5855568B2 (ja) | 2009-09-15 | 2010-09-15 | 癌の治療法 |
| JP2014223985A Withdrawn JP2015025020A (ja) | 2009-09-15 | 2014-11-04 | 癌の治療法 |
| JP2016045695A Pending JP2016106143A (ja) | 2009-09-15 | 2016-03-09 | 癌の治療法 |
| JP2017196769A Withdrawn JP2017226708A (ja) | 2009-09-15 | 2017-10-10 | 癌の治療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022135758A Withdrawn JP2022166327A (ja) | 2009-09-15 | 2022-08-29 | 癌の治療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US20110160159A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2477985B1 (cg-RX-API-DMAC7.html) |
| JP (6) | JP5855568B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN102666533A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2010295646B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112012005594A2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA2774015A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA201200486A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL218575A0 (cg-RX-API-DMAC7.html) |
| MX (2) | MX342709B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011034954A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9770517B2 (en) | 2002-03-01 | 2017-09-26 | Immunomedics, Inc. | Anti-Trop-2 antibody-drug conjugates and uses thereof |
| PT2277551E (pt) | 2002-09-06 | 2013-08-22 | Cerulean Pharma Inc | Polímeros à base de ciclodextrina para a administração de medicamentos ligados por ligação covalente |
| US10058621B2 (en) | 2015-06-25 | 2018-08-28 | Immunomedics, Inc. | Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers |
| US9707302B2 (en) | 2013-07-23 | 2017-07-18 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
| US20080176958A1 (en) | 2007-01-24 | 2008-07-24 | Insert Therapeutics, Inc. | Cyclodextrin-based polymers for therapeutics delivery |
| US20120114658A1 (en) * | 2009-09-15 | 2012-05-10 | John Ryan | Treatment of cancer |
| WO2011051894A1 (en) | 2009-10-29 | 2011-05-05 | Aventis Pharma S.A. | Novel antitumoral use of cabazitaxel |
| US20120064107A1 (en) * | 2010-05-18 | 2012-03-15 | Cerulean Pharma Inc. | Compositions and methods for treatment of autoimmune and other disease |
| EP2809686A4 (en) * | 2012-01-31 | 2015-11-25 | Cerulean Pharma Inc | POLYMERS ON CYCLODEXTRINBASIS FOR THERAPEUTIC ADMINISTRATION |
| US9382329B2 (en) | 2012-08-14 | 2016-07-05 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to Trop-2 expressing cells |
| US20140094432A1 (en) | 2012-10-02 | 2014-04-03 | Cerulean Pharma Inc. | Methods and systems for polymer precipitation and generation of particles |
| WO2014055913A1 (en) * | 2012-10-05 | 2014-04-10 | Cerulean Pharma Inc. | Treatment of cancer |
| US9931417B2 (en) | 2012-12-13 | 2018-04-03 | Immunomedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
| US12310958B2 (en) | 2012-12-13 | 2025-05-27 | Immunomedics, Inc. | Antibody-drug conjugates and uses thereof |
| US10413539B2 (en) | 2012-12-13 | 2019-09-17 | Immunomedics, Inc. | Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132) |
| US10206918B2 (en) | 2012-12-13 | 2019-02-19 | Immunomedics, Inc. | Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers |
| US20240148873A1 (en) | 2012-12-13 | 2024-05-09 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity |
| WO2015012904A2 (en) | 2012-12-13 | 2015-01-29 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
| CN104837508A (zh) | 2012-12-13 | 2015-08-12 | 免疫医疗公司 | 功效改进且毒性降低的抗体与sn-38的免疫缀合物的剂量 |
| US10137196B2 (en) | 2012-12-13 | 2018-11-27 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
| US9492566B2 (en) | 2012-12-13 | 2016-11-15 | Immunomedics, Inc. | Antibody-drug conjugates and uses thereof |
| US10744129B2 (en) | 2012-12-13 | 2020-08-18 | Immunomedics, Inc. | Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2 |
| WO2014128108A1 (de) | 2013-02-21 | 2014-08-28 | Bayer Pharma Aktiengesellschaft | Estra-1,3,5(10),16-tetraen-3-carboxamide zur inhibierung von 17.beta.-hydroxysteroid dehdrogenase (akr1 c3) |
| EP2801370A1 (en) * | 2013-05-07 | 2014-11-12 | Fundació Privada Institut d'Investigació Oncològica de Vall Hebron | Methods and compositions for the treatment of cancer |
| US11253606B2 (en) | 2013-07-23 | 2022-02-22 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
| EP3049078B1 (en) * | 2013-09-27 | 2018-06-27 | BlueLink Pharmaceuticals, Inc. | Treatment of cancer |
| BR112016016932A8 (pt) * | 2014-01-24 | 2020-06-16 | Sirtex Medical Ltd | uso de uma combinação de oxaliplatina (oxa), leucovorina (lv) e 5-fluorouracil (5-fu) |
| NZ734256A (en) * | 2015-02-12 | 2019-02-22 | Beyondspring Pharmaceuticals Inc | Use of plinabulin in combination with immune checkpoint inhibitors |
| JP6769982B2 (ja) | 2015-03-06 | 2020-10-14 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | Ｒａｓ変異と関連するがんの治療方法 |
| CA2981543A1 (en) | 2015-04-22 | 2016-10-27 | Immunomedics, Inc. | Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells |
| US10195175B2 (en) | 2015-06-25 | 2019-02-05 | Immunomedics, Inc. | Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors |
| CN108026075B (zh) | 2015-07-13 | 2021-06-29 | 大连万春布林医药有限公司 | 普那布林组合物 |
| SG10201913073YA (en) | 2015-08-20 | 2020-03-30 | Ipsen Biopharm Ltd | Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment |
| FR3040860B1 (fr) * | 2015-09-10 | 2020-05-15 | Universite de Bordeaux | Milieu de conservation injectable pour la conservation de cellules du sang placentaire, de la moelle osseuse et du sang peripherique |
| US20190133963A1 (en) * | 2015-11-03 | 2019-05-09 | Nanoproteagen | Polymeric nanoparticles |
| RU2753543C1 (ru) | 2016-02-08 | 2021-08-17 | Бейондспринг Фармасьютикалс, Инк. | Композиции, содержащие тукаресол или его аналоги |
| CN108601841A (zh) | 2016-02-10 | 2018-09-28 | 免疫医疗公司 | Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性 |
| WO2017177055A1 (en) * | 2016-04-08 | 2017-10-12 | Liang Zhao | Cyclodextrin-based polymers for therapeutic delivery |
| CN109310385A (zh) | 2016-04-27 | 2019-02-05 | 免疫医疗公司 | 抗trop-2-sn-38抗体药物缀合物用于检查点抑制剂复发/难治的肿瘤的疗法的功效 |
| EP3463337A4 (en) | 2016-06-06 | 2020-02-12 | Beyondspring Pharmaceuticals, Inc. | COMPOSITION AND METHOD FOR REDUCING NEUTROPENIA |
| WO2018102769A1 (en) * | 2016-12-01 | 2018-06-07 | Bluelink Pharmaceuticals, Inc. | Treatment of cancer |
| WO2018129381A1 (en) | 2017-01-06 | 2018-07-12 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
| SG11201907023UA (en) | 2017-02-01 | 2019-08-27 | Beyondspring Pharmaceuticals Inc | Method of reducing neutropenia |
| CA3050332A1 (en) | 2017-03-27 | 2018-10-04 | Immunomedics, Inc. | Treatment of trop-2 expressing triple negative breast cancer with sacituzumab govitecan and a rad51 inhibitor |
| WO2018187074A1 (en) | 2017-04-03 | 2018-10-11 | Immunomedics, Inc. | Subcutaneous administration of antibody-drug conjugates for cancer therapy |
| BR112020014960A2 (pt) | 2018-01-24 | 2020-12-22 | Beyondspring Pharmaceuticals, Inc. | Composição e método para redução de trombocitopenia |
| WO2019232257A1 (en) * | 2018-06-01 | 2019-12-05 | Beyondspring Pharmaceuticals, Inc. | Composition and method of treating cancer associated with egfr mutation |
| CN113164600A (zh) | 2018-10-17 | 2021-07-23 | 百欧林纳克斯有限公司 | 转移性胰脏腺癌的治疗 |
| US20220072087A1 (en) | 2019-01-17 | 2022-03-10 | Biolinerx Ltd. | Specific combination therapy for treatment of pancreatic cancer |
| WO2020148744A1 (en) | 2019-01-17 | 2020-07-23 | Biolinerx Ltd. | Combination therapy for treatment of pancreatic cancer |
| WO2021119464A1 (en) * | 2019-12-13 | 2021-06-17 | Veri Nano Inc. | Compositions and modular nano- and microparticles for the delivery of various agents and use thereof |
| JP2023511184A (ja) * | 2020-01-22 | 2023-03-16 | メドイミューン・リミテッド | 化合物及びその複合体 |
| CN117098531A (zh) * | 2021-01-08 | 2023-11-21 | 斯塔顿治疗公司 | 用于肠胃外使用的免疫调节酰亚胺化合物的稳定溶液 |
| CN114904013A (zh) * | 2021-02-08 | 2022-08-16 | 中国科学院上海药物研究所 | 硫酸乙酰肝素-骨化三醇偶联物，包含其的乙酰肝素酶响应性纳米粒，其制备方法及用途 |
| CN115109258A (zh) * | 2021-03-19 | 2022-09-27 | 江西中医药大学 | 7-乙基-10-羟基喜树碱聚合物、制备方法及其应用 |
| JP2024513505A (ja) | 2021-04-09 | 2024-03-25 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | 腫瘍を治療するための組成物及び方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3378250D1 (en) | 1982-04-22 | 1988-11-24 | Ici Plc | Continuous release formulations |
| US4438253A (en) | 1982-11-12 | 1984-03-20 | American Cyanamid Company | Poly(glycolic acid)/poly(alkylene glycol) block copolymers and method of manufacturing the same |
| JPS60100516A (ja) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
| ES2058081T3 (es) | 1986-09-05 | 1994-11-01 | American Cyanamid Co | Poliesteres que contienen bloques de oxido de alquileno como sistemas de administracion de medicamentos. |
| JP2670680B2 (ja) | 1988-02-24 | 1997-10-29 | 株式会社ビーエムジー | 生理活性物質含有ポリ乳酸系微小球およびその製造法 |
| FR2665169A1 (fr) | 1990-07-30 | 1992-01-31 | Rhone Poulenc Chimie | Composes d'inclusion de cyclodextrines enfermant des antioxydants phenoliques et leur utilisation dans les polymeres. |
| US5330768A (en) | 1991-07-05 | 1994-07-19 | Massachusetts Institute Of Technology | Controlled drug delivery using polymer/pluronic blends |
| GB9211268D0 (en) | 1992-05-28 | 1992-07-15 | Ici Plc | Salts of basic peptides with carboxyterminated polyesters |
| IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
| DE19616486C5 (de) | 1996-04-25 | 2016-06-30 | Royalty Pharma Collection Trust | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
| TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
| US5990237A (en) * | 1997-05-21 | 1999-11-23 | Shearwater Polymers, Inc. | Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines |
| AU756796B2 (en) * | 1998-10-16 | 2003-01-23 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Combination therapy with VIP antagonist |
| CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
| AUPP913999A0 (en) * | 1999-03-12 | 1999-04-01 | Biota Scientific Management Pty Ltd | Novel chemical compounds and their use |
| US6420378B1 (en) * | 1999-10-15 | 2002-07-16 | Supergen, Inc. | Inhibition of abnormal cell proliferation with camptothecin and combinations including the same |
| AU2003243561A1 (en) * | 2002-06-14 | 2003-12-31 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| US20040047835A1 (en) * | 2002-09-06 | 2004-03-11 | Cell Therapeutics, Inc. | Combinatorial drug therapy using polymer drug conjugates |
| PT2277551E (pt) * | 2002-09-06 | 2013-08-22 | Cerulean Pharma Inc | Polímeros à base de ciclodextrina para a administração de medicamentos ligados por ligação covalente |
| AU2003299651A1 (en) * | 2002-12-11 | 2004-06-30 | Merck And Co., Inc. | Tyrosine kinase inhibitors |
| US7358262B2 (en) * | 2003-01-29 | 2008-04-15 | Whitehead Institute For Biomedical Research | Identification of genotype-selective anti-tumor agents |
| CN1216057C (zh) * | 2003-03-28 | 2005-08-24 | 贵州省生物研究所 | 喜树碱类似物的衍生物及其制备方法 |
| CA2547934C (en) * | 2004-02-19 | 2013-05-21 | Abbott Laboratories | Methods of using gamma cyclodextrin to control blood glucose and insulin secretion |
| CA2569520C (en) * | 2004-06-04 | 2023-03-14 | Genentech, Inc. | Kras mutations for identifying colorectal tumors responsive to cetuximab or panitumumab |
| TW200640493A (en) * | 2005-02-16 | 2006-12-01 | Insert Therapeutics Inc | Cyclodextrin-based polymers for therapeutics delivery |
| EP1913157B2 (en) * | 2005-06-28 | 2016-10-26 | Genentech, Inc. | Egfr and kras mutations for prediction of patient response to egfr inhibitor treatment |
| US8143236B2 (en) * | 2005-12-13 | 2012-03-27 | Bionumerik Pharmaceuticals, Inc. | Chemoprotective methods |
| KR100917809B1 (ko) * | 2006-05-22 | 2009-09-18 | 에스케이케미칼주식회사 | 우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물 |
| US20100112077A1 (en) * | 2006-11-06 | 2010-05-06 | Abraxis Bioscience, Llc | Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
| WO2008148080A2 (en) * | 2007-05-24 | 2008-12-04 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical compositions of [5(s)-(2'-hydroxyethoxy)-20(s)-camptothecin] |
| US20100056555A1 (en) * | 2008-08-29 | 2010-03-04 | Enzon Pharmaceuticals, Inc. | Method of treating ras associated cancer |
| EA201171195A8 (ru) * | 2009-03-30 | 2014-08-29 | Серулин Фарма Инк. | Конъюгаты, частицы, композиции "полимер-агент" и способы их применения |
| US20120114658A1 (en) * | 2009-09-15 | 2012-05-10 | John Ryan | Treatment of cancer |
-
2010
- 2010-09-15 CA CA2774015A patent/CA2774015A1/en not_active Abandoned
- 2010-09-15 CN CN2010800410580A patent/CN102666533A/zh active Pending
- 2010-09-15 AU AU2010295646A patent/AU2010295646B2/en not_active Ceased
- 2010-09-15 US US12/883,084 patent/US20110160159A1/en not_active Abandoned
- 2010-09-15 CA CA2939165A patent/CA2939165A1/en not_active Abandoned
- 2010-09-15 WO PCT/US2010/048973 patent/WO2011034954A1/en not_active Ceased
- 2010-09-15 JP JP2012529881A patent/JP5855568B2/ja not_active Expired - Fee Related
- 2010-09-15 MX MX2012003046A patent/MX342709B/es active IP Right Grant
- 2010-09-15 MX MX2016013249A patent/MX366955B/es unknown
- 2010-09-15 BR BR112012005594A patent/BR112012005594A2/pt not_active Application Discontinuation
- 2010-09-15 EA EA201200486A patent/EA201200486A1/ru unknown
- 2010-09-15 EP EP10817784.1A patent/EP2477985B1/en active Active
-
2012
- 2012-03-11 IL IL218575A patent/IL218575A0/en unknown
-
2013
- 2013-01-10 US US13/738,630 patent/US20130338103A1/en not_active Abandoned
- 2013-02-15 US US13/769,046 patent/US20130164282A1/en not_active Abandoned
-
2014
- 2014-11-04 JP JP2014223985A patent/JP2015025020A/ja not_active Withdrawn
-
2015
- 2015-04-01 US US14/675,815 patent/US20160058875A1/en not_active Abandoned
-
2016
- 2016-03-09 JP JP2016045695A patent/JP2016106143A/ja active Pending
-
2017
- 2017-04-26 US US15/498,056 patent/US20180071404A1/en not_active Abandoned
- 2017-10-10 JP JP2017196769A patent/JP2017226708A/ja not_active Withdrawn
-
2020
- 2020-06-25 JP JP2020109574A patent/JP2020164547A/ja active Pending
-
2022
- 2022-08-29 JP JP2022135758A patent/JP2022166327A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020164547A5 (cg-RX-API-DMAC7.html) | ||
| ES2576289T3 (es) | Nanopartículas de paclitaxel y albúmina en combinación con bevacizumab contra el cáncer | |
| EP2762140B1 (en) | Treatment of solid brain tumours with a rapamycin derivative | |
| JP6761852B2 (ja) | がん治療 | |
| CA3025442C (en) | Cpf-373 protide for use in treating cancer | |
| ES2946472T3 (es) | Agente antitumoral y potenciador del efecto antitumoral | |
| NZ506187A (en) | Use of epothilones for the treatment of cancer | |
| JP5709354B2 (ja) | ｍＴＯＲ阻害剤投与によるがん患者の治療 | |
| JP6002835B2 (ja) | 低用量イリノテカン塩酸塩水和物を含有する抗腫瘍剤 | |
| JP2021505548A (ja) | 化学療法抵抗性の卵巣がんまたは乳がんの治療におけるｐａｒｐ阻害剤の使用 | |
| US8440675B2 (en) | Potentiator of radiation therapy | |
| JP2019513812A5 (cg-RX-API-DMAC7.html) | ||
| CN104968340A (zh) | 治疗肝脏疾病或病状的用途和方法 | |
| Fujitani et al. | Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer | |
| JP5976923B2 (ja) | イリノテカン塩酸塩水和物を含有する抗腫瘍剤 | |
| EP3897612A1 (en) | Treatment of breast cancer using combination therapies comprising an akt inhibitor, a taxane, and a pd-l1 inhibitor | |
| JP2011514356A5 (cg-RX-API-DMAC7.html) | ||
| Khunger et al. | Gastrointestinal Complications of Chemotherapy | |
| US11911374B2 (en) | Methods and uses for treating cancer | |
| Yoshioka et al. | Biweekly administration regimen of docetaxel combined with CPT-11 in patients with inoperable or recurrent gastric cancer | |
| JP2003535874A (ja) | 置換アクリロイルジスタマイシン誘導体、タキサン類及び／又は代謝拮抗剤を含む腫瘍に対する併用療法 | |
| US12036215B2 (en) | Antitumor agent and method for tumor therapy | |
| RU2777519C2 (ru) | Применение ингибитора parp в лечении резистентного к химиотерапии рака яичников или рака молочной железы | |
| JPWO2022103834A5 (cg-RX-API-DMAC7.html) | ||
| NZ777925A (en) | Deoxy- cytidine or uridine derivatives for use in cancer therapies |